SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-17-336447
Filing Date
2017-11-08
Accepted
2017-11-08 07:02:02
Documents
73
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d533000d10q.htm 10-Q 558083
2 EX-31.1 d533000dex311.htm EX-31.1 10072
3 EX-31.2 d533000dex312.htm EX-31.2 10149
4 EX-32.1 d533000dex321.htm EX-32.1 6265
  Complete submission text file 0001193125-17-336447.txt   4021440

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vnda-20170930.xml EX-101.INS 672127
6 XBRL TAXONOMY EXTENSION SCHEMA vnda-20170930.xsd EX-101.SCH 57785
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20170930_cal.xml EX-101.CAL 69948
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20170930_def.xml EX-101.DEF 313563
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20170930_lab.xml EX-101.LAB 411870
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20170930_pre.xml EX-101.PRE 373418
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 171185033
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences